VasoCare. Vasogen

Curr Opin Investig Drugs. 2001 Sep;2(9):1247-9.


Vasogen is developing VasoCare, an immune modulation therapy, as a potential treatment for peripheral vascular disease (PVD) and atherosclerosis [308287], [388266]. In December 1998, VasoCare was in late phase II trials in the UK for PVD [308287], and by October 2000, phase I/II trials were underway in the US, Canada and Europe [388254]. By March 2001, Vasogen was planning to launch a US multicenter trial in PVD in support of regulatory approval [402091]. In June 2001, the USPTO issued a patent entitled 'Method for Preventing and Reversing Atherosclerosis', covering the use of VasoCare in the prevention and reduction of atherosclerosis [411783].

Publication types

  • Review

MeSH terms

  • Adjuvants, Immunologic / chemistry
  • Adjuvants, Immunologic / pharmacology
  • Adjuvants, Immunologic / therapeutic use*
  • Animals
  • Clinical Trials, Phase I as Topic
  • Clinical Trials, Phase II as Topic
  • Humans
  • Peripheral Vascular Diseases / drug therapy*
  • Structure-Activity Relationship


  • Adjuvants, Immunologic